Wednesday, July 8, 2026

Drug profile · INN

urokinase

urokinase (KINLYTIC) is a urokinase-type plasminogen activator exogenous protein. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 8
Pipeline programs 0
News articles 0
Drug details — urokinase
US status
approved
Class
Route
INJECTION
Patents
8
Programs
0
Data quality
0.84

Quick answer

urokinase (KINLYTIC) is a urokinase-type plasminogen activator exogenous protein. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN urokinase
Brand KINLYTIC
Mechanism Urokinase-type plasminogen activator exogenous protein
Target Urokinase-type plasminogen activator
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Urokinase-type plasminogen activator exogenous protein

Primary target: Urokinase-type plasminogen activator

Approval history

Authority Status Date
FDA approved

Related patents

  1. US 12331334

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11613744

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10239954

    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 9695249

    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof

    Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9255155

    Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9029509

    Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR)

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8546322

    Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof

    Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 7332469

    Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions

    Expires Mon Feb 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is urokinase?

urokinase (KINLYTIC) is a urokinase-type plasminogen activator exogenous protein. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for urokinase?

KINLYTIC is a marketed brand name for urokinase. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of urokinase?

urokinase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.